Trial Profile

A Phase I/II Open-Label Study of Alpelisib (BYL719) in Combination With Carboplatin in Patients With Solid Tumors and HPV+ Squamous Cell Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 29 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary) ; Carboplatin (Primary)
Indications Carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
10 Oct 2022 Planned End Date changed from 29 Feb 2028 to 30 Apr 2028.
10 Oct 2022 Planned primary completion date changed from 29 Feb 2028 to 30 Apr 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com